Article Dans Une Revue European Journal of Clinical Pharmacology Année : 2021

Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?

Résumé

Purpose: Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated. Method: This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms. Results: In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders. Conclusion: Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs.

Fichier non déposé

Dates et versions

hal-03244134 , version 1 (01-06-2021)

Identifiants

Citer

Alexandra Jobert, Edouard Laforgue, Marie Grall-Bronnec, Morgane Rousselet, Morgane Péré, et al.. Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?. European Journal of Clinical Pharmacology, 2021, 77 (2), pp.171-177. ⟨10.1007/s00228-020-03007-7⟩. ⟨hal-03244134⟩
92 Consultations
0 Téléchargements

Altmetric

Partager

  • More